Search

everythingexperts & clinicslearnfaqsresearchcommunity

for

Search:↓

This study found that while both microneedling-assisted methotrexate and triamcinolone acetonide treatments led to improvements in recalcitrant alopecia areata, methotrexate-treated areas had significantly better outcomes in terms of SALT score reduction, patient satisfaction, and relapse rates, suggesting its superior short-term efficacy.

This study found that oral administration of Terminalia bellirica enhanced hair growth in testosterone-suppressed conditions in both human cell and mouse models, outperforming finasteride, a current commercial hair loss treatment.

Botulinum A toxin injections reduced pain and promoted hair regrowth in a woman with a rare form of alopecia areata.

This case report identifies a 23-year-old man with congenital triangular alopecia, a non-scarring alopecia characterized by preserved follicles and vellus hair, for which unnecessary interventions should be avoided.

This study highlights that while there are no FDA- or ANVISA-approved treatments for children with alopecia areata, JAK inhibitors are emerging as a promising therapeutic option for this population.

Baricitinib stops hair loss and promotes regrowth in alopecia areata.

This study found that BAMO acupuncture combined with Simiao pill can help restore normal prostate tissue structure in mice by reducing DHT production, promoting apoptosis, and decreasing inflammatory responses.

This study found that self-monitoring blood pressure among pregnant women with hypertension did not significantly improve clinical outcomes compared to usual care, though women reported positive cognitive and emotional responses.

This study found that TAZ promotes adipogenesis in goat adipose-derived mesenchymal stem cells by enhancing PI3K/AKT pathway activity, with overexpression boosting adipocyte formation and knockdown inhibiting it.

This study found that microneedling combined with calcipotriol plus betamethasone was more effective in treating vitiligo than microneedling with tacrolimus, particularly in difficult-to-treat areas.

In this case report, off-label onabotulinumtoxin-A was successfully used to treat trichodynia, a painful scalp sensation associated with hair loss, in a patient unresponsive to conventional therapies.

This case report discusses a successful treatment of Alopecia Areata with tofacitinib and includes a literature review on the condition's pathophysiology and the mechanism of JAK inhibitors, though it notes the high failure rate of available treatments and absence of FDA-approved options.

This study reported that six out of seven pediatric patients with refractory patchy alopecia areata experienced significant hair regrowth after one month of oral tofacitinib treatment, suggesting it may be an effective and safe option, although larger studies are needed to evaluate long-term safety.

This study observed initial hair regrowth in a businessman with alopecia areata universalis treated with tofacitinib, but the effect diminished, leading to renewed hair loss.

This systematic review suggests that botulinum toxin may be effective for treating certain scalp conditions, but the current evidence varies widely in quality and often derives from small observational studies.

In this study, researchers found that ritlecitinib 50 mg offered a lower cost per responder than baricitinib 2 or 4 mg at both 24 and 52 weeks for treating severe alopecia areata, suggesting potential implications for reimbursement or formulary decisions.

This study retrospectively evaluated the effectiveness of off-label baricitinib in children with severe alopecia areata and found that 50% achieved treatment goals, though psychological effects were noted and laboratory abnormalities occurred in 42.86% of patients.

Congenital triangular alopecia is more common than thought and some treatments can be beneficial for appearance concerns.

In this randomized study, 72% of patients treated with 0.05% betamethasone dipropionate showed significant improvement in limited patchy alopecia areata compared to 36% of those using 0.05% tretinoin, suggesting BMD is more effective but further research on tretinoin is needed.

This study found that oral tofacitinib was effective in promoting hair regrowth in patients with alopecia universalis, although further controlled studies are recommended to confirm its safety and efficacy.

This study found that off-pump coronary surgery significantly reduces in-hospital morbidity compared to on-pump surgery without affecting midterm outcomes in the first 1-3 years after the procedure.

Baricitinib effectively stops hair loss and promotes regrowth in acute alopecia areata.

This case report describes a child with alopecia areata and atopic dermatitis who showed significant improvement after treatment with baricitinib and corticosteroid ointment, suggesting their potential efficacy and safety.

In this study, tofacitinib treatment was associated with significant hair regrowth in two patients with alopecia universalis over eight months, with minimal adverse effects reported.

This study found that baricitinib improved symptoms of atopic dermatitis and alopecia areata in both adults and children in real-world settings, aligning with clinical trial results, while noting low discontinuation due to adverse events and no new safety concerns.

Brepocitinib improves cicatricial alopecia and reduces key immune markers.

In this study, TASP0382088 showed potent selective inhibition of the ALK5 receptor, significantly reducing Smad2 phosphorylation in mouse skin following topical application.

Topical tofacitinib helped a man with severe scalp condition after other treatments failed.